Jones Financial Companies Lllp Acquires 817 Shares of Guardant Health, Inc. (NASDAQ:GH)

Jones Financial Companies Lllp increased its holdings in Guardant Health, Inc. (NASDAQ:GH) by 43.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,696 shares of the company’s stock after acquiring an additional 817 shares during the quarter. Jones Financial Companies Lllp’s holdings in Guardant Health were worth $82,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. R Squared Ltd bought a new position in shares of Guardant Health in the 4th quarter worth about $26,000. Van ECK Associates Corp grew its position in Guardant Health by 47.4% during the 4th quarter. Van ECK Associates Corp now owns 2,887 shares of the company’s stock valued at $88,000 after purchasing an additional 929 shares during the last quarter. KBC Group NV grew its position in Guardant Health by 63.6% during the 4th quarter. KBC Group NV now owns 5,658 shares of the company’s stock valued at $173,000 after purchasing an additional 2,200 shares during the last quarter. Guyasuta Investment Advisors Inc. purchased a new stake in Guardant Health during the 4th quarter valued at about $206,000. Finally, Wealthcare Advisory Partners LLC purchased a new stake in Guardant Health during the 4th quarter valued at about $252,000. 92.60% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

GH has been the topic of several recent analyst reports. Scotiabank increased their price objective on shares of Guardant Health from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research report on Monday, February 24th. Morgan Stanley increased their price objective on shares of Guardant Health from $42.00 to $52.00 and gave the company an “overweight” rating in a research report on Thursday, March 6th. Guggenheim reissued a “buy” rating and set a $56.00 price objective on shares of Guardant Health in a research report on Monday, February 24th. JPMorgan Chase & Co. raised their price target on shares of Guardant Health from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Finally, Canaccord Genuity Group boosted their price objective on shares of Guardant Health from $42.00 to $60.00 and gave the company a “buy” rating in a report on Monday, February 24th. Twenty analysts have rated the stock with a buy rating, According to MarketBeat.com, Guardant Health has an average rating of “Buy” and a consensus target price of $48.40.

Guardant Health Trading Up 5.5 %

Shares of GH stock opened at $42.89 on Monday. The company has a 50 day simple moving average of $43.01 and a two-hundred day simple moving average of $32.94. The stock has a market cap of $5.29 billion, a P/E ratio of -12.05 and a beta of 1.50. Guardant Health, Inc. has a 12 month low of $15.81 and a 12 month high of $50.89.

Guardant Health (NASDAQ:GH) last released its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The firm had revenue of $201.81 million during the quarter, compared to analysts’ expectations of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. As a group, equities analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.